一、长期股权激励计划的概况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及全体董事会成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 1、实施背景 广东英联包装股份有限公司（以下简称"公司"、"英联股份"）于2023年1月16日召开2023年第一次临时 股东大会，审议通过《关于对外投资建设新能源汽车动力锂电池复合铜箔、铝箔项目的议案》，对外投 资30.89亿元建设新能源汽车动力锂电池复合铜箔、复合铝箔项目（以下简称"复合集流体项目"），达 产后年产能预计达到5亿㎡复合铜箔、1亿㎡复合铝箔。 公司于2023年2月在江苏省扬州高邮市成立控股子公司江苏英联复合集流体有限公司（以下简称"江苏英 联"）作为复合集流体项目实施主体，搭建了一支由博士、硕士领衔，覆盖真空物理、光学膜、柔性材 料等方面专业经验的技术开发团队，保障复合集流体产品研发工作的有序推进；在供应端方面积极推动 产业链协同，积极推动产业交流、共享。 截至目前，在产能建设方面，江苏英联已具备5条日本爱发科复合铝箔生产线，5条复合铜箔生产线。公 司有序推进复合集流体项目，筹备量产的生产条件，全方位运营管理，为产业化发展 ...

Group 1 - The core point of the news is the announcement of the progress of the long-term equity incentive plan for Jiangsu Yinglian Recombined Fluid Co., Ltd., a subsidiary of Guangdong Yinglian Packaging Co., Ltd. [2][4] - The long-term equity incentive plan aims to motivate and retain core talents, aligning their interests with the company's long-term development goals [4][13] - The company has established a technical development team for the Recombined Fluid Project, which includes experts in various fields to ensure the orderly advancement of product research and development [2][3] Group 2 - The first phase of the equity incentive plan is currently in progress, with adjustments made due to some participants no longer meeting the eligibility criteria [7] - The second phase of the equity incentive plan has been approved, with a total of 500 million yuan in registered capital, of which 1% will be allocated to the incentive plan [8][9] - The performance assessment criteria for the second phase will include both company-level and individual-level metrics, ensuring that the incentive plan is closely tied to performance [11]

Core Viewpoint - Company is facing short-term performance pressure due to increased impairment losses and strategic investments, with a significant decline in net profit expected for 2025 [1][3] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of between 101 million and 151 million yuan for 2025, representing a year-on-year decline of 53% to 69% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 57.5 million and 85.97 million yuan, reflecting a year-on-year decrease of 74% to 82% [1] - A one-time non-cash impairment loss of 195 million yuan was recognized for assets related to the Best Formulation personal care business [1] - The company confirmed an investment impairment loss of 56.55 million yuan due to underperformance of a brand operation company, impacting the non-recurring net profit more significantly than the attributable net profit [1] Group 2: Strategic Initiatives - The company plans to grant 2.2025 million shares to 85 management and core technical personnel at a price of 12.21 yuan per share, with performance targets set for revenue growth in 2026, 2027, and 2028 [2] - An employee stock ownership plan will be implemented for up to 12 individuals, with profit targets for 2026 and 2027 set at no less than 380 million yuan and 450 million yuan, respectively [2] - These initiatives aim to clarify the company's operational goals for the next three years, enhancing market confidence and stabilizing expectations [2] Group 3: Market Position and Growth Outlook - As a leading company in the domestic nutrition and health food sector, the company is adjusting its operations to focus on customer and regional expansion, which is expected to support stable growth in its core business [3] - The strategic layout in precision nutrition and pet nutrition is designed to create a second growth curve for the company [3] - Revenue projections for 2025 to 2027 are estimated at 4.51 billion, 5.12 billion, and 5.61 billion yuan, with year-on-year growth rates of 7%, 14%, and 10%, respectively [3] - Expected net profits for 2025 to 2027 are projected at 130 million, 380 million, and 450 million yuan, with year-on-year growth rates of -61%, 204%, and 18%, respectively [3]

在2025年度履职期间，张敏共亲自出席了4次董事会会议及3次独立董事专门会议，对所有审议议案均投 出赞成票，未提出异议。其履职重点关注事项包括：公司2025年第三季度报告的编制与披露，确保财务 数据真实准确；以及公司根据授权注销2023年及2025年股票期权激励计划中部分股票期权的相关事项， 确认其程序合法合规。张敏通过现场办公、与管理层及审计机构沟通等方式，深入了解公司经营状况。 报告指出，张敏的任职符合独立性要求，其履职行为有效促进了公司治理的规范运作。展望2026年，张 敏表示将继续加强学习，恪尽职守，以促进公司持续健康发展，并感谢董事会及管理层的支持与配合。 中访网数据 北京指南针科技发展股份有限公司于近日披露了独立董事张敏的2025年度述职报告。报告 显示，张敏自2025年10月任职以来，严格按照相关法律法规及《公司章程》勤勉履职，积极参与公司决 策，切实维护公司整体利益及中小股东权益。 ...

Core Viewpoint - The recent share reduction plans by executives and the employee stock ownership plan of Changying Precision have raised market concerns regarding potential "high sell low buy" strategies, but the company clarifies that these actions are primarily driven by personal financial needs and long-term commitment to the company's growth [1][2]. Group 1: Executive Share Reduction - Three executives plan to reduce their shares acquired from the 2013 stock option incentive plan, with a total reduction of 163,000 shares, representing 0.018% of the company's total share capital at the time of reduction [2]. - The remaining two executives' shares were purchased from the secondary market before 2019, reflecting their confidence in the company's future during a business adjustment period, and they have not sold shares during their tenure [2]. Group 2: Employee Stock Ownership Plan - The sixth employee stock ownership plan includes up to 31 participants, with middle management and technical staff accounting for 70.60% of the total subscription amount, which is 42.3543 million shares [2]. - The company aims to align the interests of management and employees with long-term corporate goals through this plan, enhancing motivation and value creation [1][2]. Group 3: Stock Option Incentive Plan - The draft of the 2025 stock option incentive plan proposes granting 14.262 million stock options to 870 individuals, including middle management and key technical personnel [3]. - The plan sets clear operational targets, aiming for a minimum revenue growth rate of 18% by 2026 and 28% by 2027, with cumulative revenue targets to be met for the options to be exercised [3]. Group 4: Business Growth and Transformation - Changying Precision is transitioning from traditional consumer electronics to emerging fields, establishing a dual pillar structure of consumer electronics and new energy, alongside artificial intelligence [4]. - The company has made significant progress in the humanoid robot sector, establishing partnerships with major clients in North America and Europe, and has begun mass production with over 1,000 supplied part numbers [4]. - The company anticipates continued revenue growth in the humanoid robot business by 2026, supported by increased demand and expansion of its manufacturing capabilities [4].

Group 1 - The company Guangzhi Technology announced an earnings forecast on January 30, expecting a net profit loss attributable to shareholders of 30 million to 43 million yuan for 2025, marking a shift from profit to loss year-on-year [1] - The increase in management expenses compared to the same period last year is driven by two main factors: the advancement of significant asset restructuring, leading to higher intermediary service fees, and the implementation of an equity incentive plan to motivate the core team, resulting in increased share-based payment expenses [1] - The company continues to view technological innovation as the core driver of sustained growth, with ongoing increases in R&D investment during the reporting period, leading to a rise in R&D expenses compared to the previous year [1]

Core Viewpoint - The company, Baicheng Pharmaceutical, anticipates a net profit loss attributable to shareholders of 66 to 96 million yuan for the fiscal year 2025, compared to a loss of 52.74 million yuan in the same period last year [1] Financial Performance - The net profit loss after deducting non-recurring gains and losses is expected to be between 79 to 110 million yuan, compared to a loss of 72.63 million yuan in the previous year [1] - The company's revenue from its generic drug business has declined year-on-year due to the impact of policies such as centralized procurement and the MAH (Marketing Authorization Holder) system, leading to a decrease in gross profit margin [1] Management Expenses - Management expenses for the fiscal year 2025 are projected to increase year-on-year, primarily due to the absence of a reversal of previously accrued share-based payment expenses, which had resulted in lower management expenses in 2024 [1]

事项： 公司发布2025 年业绩预告及2026 年激励计划。（1）发布业绩预告：25 年预计实现归母净利润1.01 至 1.51 亿元，同比-68.85 至-53.44%；扣非归母净利润0.58 至0.86 亿元，同比-82.45 至-73.77%，主要系 BFPC 及对湖北怡本荟的长期股权投资计提资产减值准备扰动。（2）发布2026 年限制性股票激励计 划： 拟以12.21 元/股的价格授予220.25 万股，占当前股本总数的0.72%，覆盖85名管理及核心技术人员（含 外籍骨干），26-28 年100%解锁的营收目标分别不低于50.90/53.83/58.32 亿元。（3）发布2026 年员工 持股计划：总份数不超过3205.75 万份，覆盖不超过12 名核心管理层，26-27 年100%解锁目标分别为 2026 年净利润（具体口径见附录表格，后同）不低于3.8 亿元，2027 年不低于4.5 亿元或26-27 年累计 净利润不低于8.3 亿元。（4）修订2023/2025 股权激励计划：针对23 年激励计划，将26 年100%解锁营 收目标从55.66 亿元调整至50.90 亿元；针对25 年激励计划， ...

2026年1月30日，科创新源（sz300731）触及涨停，涨停价69.92元，涨幅19.99%，总市值88.40亿元，流 通市值84.03亿元，截止发稿，总成交额14.43亿元。 根据喜娜AI异动分析，科创新源涨停原因可能如下，新能源业务+股权激励+业绩增长： 1、公司基本面 整体稳健，新能源业务增长强劲。2025年前三季度归母净利润同比增长153.29%，动力电池散热液冷板 业务表现突出，2025年年报显示盈利大幅增加，归母净利润3000万 - 4000万，同比73.62% - 131.49%。 这表明新能源业务为公司带来显著业绩提升，是股价上涨的重要动力。 2、公司实施股权激励计划，覆 盖19名核心员工，并设置2026 - 2028年净利润增长50%/100%/200%的高目标。此计划彰显了公司对未来 发展的信心，激励员工为实现目标而努力，有利于提升公司的运营效率和盈利能力。 3、从市场板块表 现来看，近期新能源汽车产业链相关个股表现活跃，资金关注度较高。科创新源与宁德时代合作关系持 续巩固，且汽车密封条业务增长，欧式导槽工艺产品进入大批量交付阶段，收入规模快速提升，契合当 前市场热点。技术面上，若该股 ...

Core Viewpoint - Yirui Technology (688301.SH), a manufacturer of digital X-ray detectors, achieved record high performance in 2025, with significant revenue and profit growth driven by stable growth in its digital X-ray detector business and substantial growth in comprehensive solutions and core components [2][4]. Financial Performance - In 2025, the company reported revenue of 2.299 billion yuan, a year-on-year increase of 25.53% - The net profit attributable to shareholders reached 661 million yuan, up 42.15% - The net profit after deducting non-recurring gains and losses was 627 million yuan, reflecting a growth of 42.89% [2][4]. Market Position - Yirui Technology holds a leading position in the global market for digital X-ray detectors, with a market share of 19.83% in 2024, up from 16.46% in 2021 [3]. - The company has consistently ranked first in market share within China for digital X-ray detectors [3]. Employee Incentives - The company is implementing a multi-tiered incentive system to enhance talent development and bind the core team, promoting long-term growth [6]. - A 2026 employee stock ownership plan has been proposed, with an initial cap of 150 participants and a funding limit of 100 million yuan, linked to performance targets based on 2025 net profit [6][7]. Strategic Investments - In October 2025, Yirui Technology raised 1.16 billion yuan through a private placement to fund projects related to X-ray vacuum devices and comprehensive solutions [5]. - The total assets of the company reached 12.79 billion yuan by the end of 2025, a 40.81% increase from the previous year [5]. Subsidiary Development - Yirui Hefei, a wholly-owned subsidiary, is set to introduce strategic investors through a 500 million yuan capital increase, enhancing its financial strength and operational scale [8][9]. - The introduction of local state-owned investors is expected to deepen strategic cooperation and improve the subsidiary's market competitiveness [8].